Antibody association with HER-2/neu–targeted vaccine enhances CD8+ T cell responses in mice through Fc-mediated activation of DCs
Open Access
- 1 May 2008
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 118 (5), 1700-1711
- https://doi.org/10.1172/jci34333
Abstract
The pathogenic nature of cancer is attributed, at least in part, to the ability of tumors cells to induce systemic and local mechanisms of immune tolerance. However, we previously reported that tumor-free survival in up to 100% of tolerized HER-2/neu transgenic mice can be achieved by administration of neu-specific mAb concurrently with a HER-2/neu–expressing, GM-CSF–secreting whole cell vaccine. In this report, we show that one mechanism of improved antitumor activity induced by the combination of these 2 neu-targeted interventions was enhanced Fc-mediated activation of APCs. Specifically, in vivo studies demonstrated localization of radiolabeled neu-specific mAb at the vaccine site. Subsequently, increased accumulation of neu-specific mAb at the vaccine-draining lymph node correlated with increased vaccine cell uptake by DCs in vivo. This led to enhancement of CD8+ neu-specific T cell function in terms of proliferation, cytokine production, and central memory development. Thus, the administration of a neu-specific mAb with a neu-targeted GM-CSF–secreting tumor vaccine enhanced induction of neu-specific CD8+ T cells through Fc-mediated activation of DCs. This multimodality attack on the same tumor antigen may have the potential to overcome tolerance to self antigens and weaken the immunosuppressive networks within the tumor microenvironment.This publication has 50 references indexed in Scilit:
- Regulatory T cells and cancerCurrent Opinion in Immunology, 2007
- Differential Antigen Processing by Dendritic Cell Subsets in VivoScience, 2007
- Central tolerance: good but imperfectImmunological Reviews, 2006
- Neoadjuvant Trastuzumab Induces Apoptosis in Primary Breast CancersJournal of Clinical Oncology, 2005
- Smoldering and polarized inflammation in the initiation and promotion of malignant diseaseCancer Cell, 2005
- Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular LymphomaJournal of Clinical Oncology, 2003
- Constitutive versus Activation-dependent Cross-Presentation of Immune Complexes by CD8+ and CD8− Dendritic Cells In VivoThe Journal of Experimental Medicine, 2002
- Inducing Tumor Immunity through the Selective Engagement of Activating Fcγ Receptors on Dendritic CellsThe Journal of Experimental Medicine, 2002
- CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cellsLeukemia, 2001
- A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodiesNuclear Medicine and Biology, 1995